权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancer

用于早期乳腺癌检测和预测的综合液体活检平台

基本信息

批准号：
9631128
负责人：
Ashutosh Agarwal
金额：
$ 58.75万
依托单位：
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-13 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9631128
关键词：
Address Advanced Malignant Neoplasm Algorithmic Analysis Algorithms Area Basic Science Biology Blood Blood specimen Breast Cancer Patient Caliber Cancer Patient Cells Cellular Morphology Cessation of life Clinical Clinical Management Clinical Pathology Clinical Research Collaborations Collection Competence Computer software Data Detection Diagnosis Diagnostic Disease Early Intervention Engineering Evaluation Fibroblasts Fluorescence Funding Mechanisms Health Hematopoietic Neoplasms Human Image Imaging problem Incidence Individual Institutes Laboratories Malignant Neoplasms Microscope Microscopy Minnesota Neoplasm Circulating Cells Neoplasm Metastasis Outcome Pathologist Patients Play Population Process Recurrence Reporting Research Research Personnel Resolution Resources Risk Role Sampling Scanning Serum Shapes Solid Neoplasm Surface Technology Time Training Universities Whole Blood analytical tool arm base cancer cell clinical Diagnosis deep learning expectation experience follow-up high resolution imaging imaging modality improved indexing individual patient industry partner liquid biopsy malignant breast neoplasm multidisciplinary neoplastic cell new technology novel novel strategies novel therapeutics oncology outcome prediction personalized medicine prognostic prognostic tool response screening success tool treatment planning treatment response tumor tumor microenvironment tumor progression virtual

项目摘要

Project Summary We seek to develop robust platforms for capturing, enumerating and analyzing circulating tumor cells and associated cancer cells from the blood of cancer patients. We will leverage our previously developed precisely engineered microfilter platform that allows effective separation and collection of viable CTC from patient blood. In parallel, we have developed novel imaging methods perfectly suited for rapid analyses for circulating tumor cells, clusters and associated cancer cell subtypes (such as Cancer Associated Fibroblasts, or CAF). We propose to integrate these two novel technologies to create a robust diagnostic tool for clinical pathology as well as basic research that enables capture, enumeration, and analyses of circulating tumor cells and associated cancer cells. Our multidisciplinary team proposes the following Specific Aims: 1) Build and validate the technology to rapidly acquire CTC/CAF images using Fourier Ptychographic Microscopy and evaluate the images with a deep learning algorithm 2) Evaluation of the integrated platform for using CTC/CAF in predicting recurrence/survival in early stage breast cancer patients For these studies in early stage breast cancer, we have robust collaborations with industry partners in Circulogix Inc (Microfilter technology for cell capture), ClearBridge Inc. (FPM imaging of the microfilter surface), and Google Software (Deep learning algorithm for analyzing FPM images of microfilter). The ability to reliably and rapidly detect and analyze CTC and associated cancer cells in early stage breast cancer patients would deliver a major new tool for oncology research, a platform for screening of novel drugs, and a critical advance in precision cancer management.

项目摘要我们寻求开发强大的平台来捕获、计数和分析循环中的肿瘤细胞和癌症患者血液中的相关癌细胞。我们将精确地利用我们之前开发的设计的微过滤器平台，可有效分离和收集患者血液中的活性CTC。同时，我们开发了新的成像方法，非常适合循环肿瘤的快速分析。细胞、簇和相关的癌细胞亚型(如癌症相关成纤维细胞，或CAF)。我们建议将这两种新技术结合起来，创建一种强大的临床病理学诊断工具。以及能够捕获、计数和分析循环中的肿瘤细胞和相关的癌细胞。我们的多学科团队提出了以下具体目标： 1)建立并验证了利用傅立叶快速获取CTC/CAF图像的技术印刷术利用深度学习算法对图像进行显微分析和评价 2)CTC/CAF早期预测复发/生存综合平台的评价乳腺癌患者对于这些早期乳腺癌的研究，我们与行业合作伙伴在 Circulogix Inc.(用于细胞捕获的微滤器技术)，ClearBridge Inc.(微滤器表面的FPM成像)，和Google Software(用于分析微滤器的FPM图像的深度学习算法)。可靠、快速检测和分析早期乳腺CTC及相关癌细胞的能力癌症患者将为肿瘤学研究提供一个重要的新工具，一个筛选新药的平台，以及在癌症精确治疗方面的关键进展。